Plant-produced SARS-CoV-2 receptor binding domain (RBD) variants showed differential binding efficiency with anti-spike specific monoclonal antibodies

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is responsible for the ongoing coronavirus disease (COVID-19) pandemic which is characterized by respiratory illness and severe pneumonia, and currently accounts for > 2.5 million deaths worldwide. Recently, diverse mutations in the spi...

Full description

Bibliographic Details
Main Authors: Kaewta Rattanapisit, Christine Joy I. Bulaon, Narach Khorattanakulchai, Balamurugan Shanmugaraj, Kittikhun Wangkanont, Waranyoo Phoolcharoen
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2021-01-01
Series:PLoS ONE
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8357147/?tool=EBI
id doaj-93b1fd1a51ed4cdc957503724b8c3782
record_format Article
spelling doaj-93b1fd1a51ed4cdc957503724b8c37822021-08-14T04:30:54ZengPublic Library of Science (PLoS)PLoS ONE1932-62032021-01-01168Plant-produced SARS-CoV-2 receptor binding domain (RBD) variants showed differential binding efficiency with anti-spike specific monoclonal antibodiesKaewta RattanapisitChristine Joy I. BulaonNarach KhorattanakulchaiBalamurugan ShanmugarajKittikhun WangkanontWaranyoo PhoolcharoenSevere acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is responsible for the ongoing coronavirus disease (COVID-19) pandemic which is characterized by respiratory illness and severe pneumonia, and currently accounts for > 2.5 million deaths worldwide. Recently, diverse mutations in the spike protein of SARS-CoV-2 were reported in United Kingdom (Alpha) and South Africa (Beta) strains which raise concerns over the potential increase in binding affinity towards the host cell receptor and diminished host neutralization capabilities. In order to study the effect of mutation in the binding efficiency of SARS-CoV-2 receptor binding domain (RBD) with anti-SARS-CoV/CoV-2 monoclonal antibodies (mAbs), we have produced SARS-CoV-2 RBD and two variants SARS-CoV-2 RBD (Alpha RBD and Beta RBD) in Nicotiana benthamiana by transient expression. Plant-produced SARS-CoV-2 RBD-Fc, Alpha RBD-Fc and Beta RBD-Fc exhibited specific binding to human angiotensin converting enzyme 2 (ACE2) receptor determined by ELISA. Intriguingly, the binding of plant-produced SARS-CoV-2 RBD proteins to plant-produced mAbs CR3022, B38, and H4 was found to be different depending on the variant mutation. In contrary to the plant-produced SARS-CoV-2 RBD-Fc and Alpha RBD-Fc, Beta RBD-Fc variant showed weak binding affinity towards the mAbs. The result suggested that the Beta RBD variant might have acquired partial resistance to neutralizing antibodies compared to other variants. However, further studies with sera from convalescent or vaccinated individuals are required to confirm this finding.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8357147/?tool=EBI
collection DOAJ
language English
format Article
sources DOAJ
author Kaewta Rattanapisit
Christine Joy I. Bulaon
Narach Khorattanakulchai
Balamurugan Shanmugaraj
Kittikhun Wangkanont
Waranyoo Phoolcharoen
spellingShingle Kaewta Rattanapisit
Christine Joy I. Bulaon
Narach Khorattanakulchai
Balamurugan Shanmugaraj
Kittikhun Wangkanont
Waranyoo Phoolcharoen
Plant-produced SARS-CoV-2 receptor binding domain (RBD) variants showed differential binding efficiency with anti-spike specific monoclonal antibodies
PLoS ONE
author_facet Kaewta Rattanapisit
Christine Joy I. Bulaon
Narach Khorattanakulchai
Balamurugan Shanmugaraj
Kittikhun Wangkanont
Waranyoo Phoolcharoen
author_sort Kaewta Rattanapisit
title Plant-produced SARS-CoV-2 receptor binding domain (RBD) variants showed differential binding efficiency with anti-spike specific monoclonal antibodies
title_short Plant-produced SARS-CoV-2 receptor binding domain (RBD) variants showed differential binding efficiency with anti-spike specific monoclonal antibodies
title_full Plant-produced SARS-CoV-2 receptor binding domain (RBD) variants showed differential binding efficiency with anti-spike specific monoclonal antibodies
title_fullStr Plant-produced SARS-CoV-2 receptor binding domain (RBD) variants showed differential binding efficiency with anti-spike specific monoclonal antibodies
title_full_unstemmed Plant-produced SARS-CoV-2 receptor binding domain (RBD) variants showed differential binding efficiency with anti-spike specific monoclonal antibodies
title_sort plant-produced sars-cov-2 receptor binding domain (rbd) variants showed differential binding efficiency with anti-spike specific monoclonal antibodies
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2021-01-01
description Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is responsible for the ongoing coronavirus disease (COVID-19) pandemic which is characterized by respiratory illness and severe pneumonia, and currently accounts for > 2.5 million deaths worldwide. Recently, diverse mutations in the spike protein of SARS-CoV-2 were reported in United Kingdom (Alpha) and South Africa (Beta) strains which raise concerns over the potential increase in binding affinity towards the host cell receptor and diminished host neutralization capabilities. In order to study the effect of mutation in the binding efficiency of SARS-CoV-2 receptor binding domain (RBD) with anti-SARS-CoV/CoV-2 monoclonal antibodies (mAbs), we have produced SARS-CoV-2 RBD and two variants SARS-CoV-2 RBD (Alpha RBD and Beta RBD) in Nicotiana benthamiana by transient expression. Plant-produced SARS-CoV-2 RBD-Fc, Alpha RBD-Fc and Beta RBD-Fc exhibited specific binding to human angiotensin converting enzyme 2 (ACE2) receptor determined by ELISA. Intriguingly, the binding of plant-produced SARS-CoV-2 RBD proteins to plant-produced mAbs CR3022, B38, and H4 was found to be different depending on the variant mutation. In contrary to the plant-produced SARS-CoV-2 RBD-Fc and Alpha RBD-Fc, Beta RBD-Fc variant showed weak binding affinity towards the mAbs. The result suggested that the Beta RBD variant might have acquired partial resistance to neutralizing antibodies compared to other variants. However, further studies with sera from convalescent or vaccinated individuals are required to confirm this finding.
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8357147/?tool=EBI
work_keys_str_mv AT kaewtarattanapisit plantproducedsarscov2receptorbindingdomainrbdvariantsshoweddifferentialbindingefficiencywithantispikespecificmonoclonalantibodies
AT christinejoyibulaon plantproducedsarscov2receptorbindingdomainrbdvariantsshoweddifferentialbindingefficiencywithantispikespecificmonoclonalantibodies
AT narachkhorattanakulchai plantproducedsarscov2receptorbindingdomainrbdvariantsshoweddifferentialbindingefficiencywithantispikespecificmonoclonalantibodies
AT balamuruganshanmugaraj plantproducedsarscov2receptorbindingdomainrbdvariantsshoweddifferentialbindingefficiencywithantispikespecificmonoclonalantibodies
AT kittikhunwangkanont plantproducedsarscov2receptorbindingdomainrbdvariantsshoweddifferentialbindingefficiencywithantispikespecificmonoclonalantibodies
AT waranyoophoolcharoen plantproducedsarscov2receptorbindingdomainrbdvariantsshoweddifferentialbindingefficiencywithantispikespecificmonoclonalantibodies
_version_ 1721207786298146816